18:27 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said that although ADVM-043 was well tolerated among six patients in the open-label, U.S....
14:45 , Nov 2, 2018 |  BC Extra  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) sank $1.21 (27%) to $3.34 on Friday after it said it will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said late Thursday...
07:00 , Aug 9, 2016 |  BC Extra  |  Company News

Editas, Adverum partner to treat retinal diseases

Editas Medicine Inc. (NASDAQ:EDIT) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) will collaborate to develop gene editing-based treatments for up to five inherited retinal diseases. The deal combines Adverum's next-generation adeno-associated viral (AAV) vectors with Editas' genome...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

Avalanche completed its acquisition of Annapurna for about $105.6 million in a stock deal and renamed the combined company as Adverum Biotechnologies Inc. (see BioCentury, Feb. 8). Annapurna Therapeutics S.A.S. , Paris, France   Avalanche...
01:45 , May 5, 2016 |  BC Extra  |  Company News

Management tracks

Gene therapy company uniQure N.V. (NASDAQ:QURE) named Paul Firuta chief commercial officer. He was chief commercial officer at BioBlast Pharma Ltd. (NASDAQ:ORPN). Metabolic company Orexigen Therapeutics Inc. (NASDAQ:OREX) named Brian Longstreet SVP of global market...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

Avalanche will acquire Annapurna, gaining four preclinical adeno-associated virus (AAV) gene therapy programs. The programs include ANN-001 , an AAV vector delivering alpha-1 antitrypsin ( AAT ; A1AT ; SERPINA1 ) to treat AAT deficiency;...
02:48 , Feb 2, 2016 |  BC Extra  |  Company News

Avalanche acquires Annapurna

Avalanche Biotechnologies Inc. (NASDAQ:AAVL) will acquire Annapurna Therapeutics S.A.S. (Paris, France), gaining four preclinical gene therapy programs outside of ophthalmology. Annapurna shareholders will receive 17.6 million new Avalanche shares, worth about $105.6 million based on...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
01:32 , Jan 7, 2016 |  BC Extra  |  Company News

Management tracks

Fertility company OvaScience Inc. (NASDAQ:OVAS) named Harald Stock CEO, effective July 1. Stock will replace Michelle Dipp, who will become executive chairman. Stock was president and CEO of ArjoHuntleigh Inc. (Malmo, Sweden). Oncology play Blueprint...
01:46 , Dec 2, 2015 |  BC Extra  |  Company News

Management tracks

Opthalmology company Avalanche Biotechnologies Inc. (NASDAQ:AAVL) hired Paul Cleveland as CEO, effective Dec. 9. Cleveland was CEO at Celladon Corp. (NASDAQ:CLDN). Oncology and inflammation play Zai Laboratory Ltd. (Shanghai, China) named Qi Liu CMO. Liu...